Bio-Matrix' new 15,000 sq. ft. facility, located in the heart of the San Diego biotechnology corridor, is currently in the process of being upgraded in order to house the Company's state-of-the-art secure Cryogenic Stem Cell Bank, 3 Research labs, aseptic cellular/tissue processing rooms, hematology, microbiology and flow cytometry laboratories.

Dr. Geoffrey O'Neill, President of Bio-Matrix, stated, "We intend for The Bio-Matrix' laboratories to be a state-of-the-art, good manufacturing practices (cGMP) and good tissue practices (cGTP) compliant facility. The Company has contracted with Carda Construction, which is a San Diego-based Construction Company and experts in Laboratory and Clean Room construction."

Bio-Matrix' Managing Director, Brian Pockett, stated, "This represents a major milestone towards full cryogenic operations. We believe that the construction of Cryogenic labs and new clean rooms will assure the superior competitiveness of Bio-Matrix and the company's greater responsiveness to the growing demand for Stem Cell Cryogenics in an increasingly strong market."

About Bio-Matrix Scientific Group Inc.

Bio-Matrix Scientific Group Inc. is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Other companies in the same industry as Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) are Cord Blood America (OTCBB:CBAI), StemCells Inc. (Nasdaq:STEM) and Regeneration Technologies (OTCBB:RTIX).

DISCLAIMER: This news release contains forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.